Outset Medical, Inc. (OM) Earnings Call Transcript & Summary
November 4, 2026
Earnings Call Speaker Segments
Executive
executiveGood afternoon, everyone, and thanks for joining us for Outset Medical's Third Quarter 2026 Earnings Call. Speaking today will be Leslie Trigg, our Chair and Chief Executive Officer, along with Renee Gaeta, our Chief Financial Officer. After the market closed today, the company put out a news release, and you can find it in the Investors section of outsetmedical.com. This call is being recorded, and it will be archived there too. All forward-looking statements we make on today's call are intended to be protected under the Private Securities Litigation Reform Act of 1995. Outset undertakes no obligation to update these statements; for a list and description of the risks and uncertainties associated with the business, please refer to Outset's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. I'll now hand the call over to Leslie Trigg.
Leslie Trigg
executiveGood afternoon, everyone, and thanks for being with us. In the third quarter our team performed strongly, making solid headway on our strategic priorities. Equally important, we keep doing the foundational work that makes the business stronger and brings our teams into alignment so we can generate growth that is more predictable and more profitable. I have confidence that these efforts are putting Outset in position to seize the considerable opportunity in front of us. With that, I'll go straight into the third quarter results, starting with financial performance. Revenue came in at $33.6 million, which was 14% higher than a year ago and 6% higher than the prior quarter. Every one of our revenue line items added to growth on both a year-over-year and a sequential basis; we were especially pleased to see console revenue rise 26% year-over-year, powered by sales of new and refreshed consoles. On recurring revenue: besides a healthy treatment volume, sales of our EMR offering are beginning to ramp and rose 23% year-over-year. Operational initiatives that are ongoing lifted non-GAAP gross margin, and discipline on expenses produced substantial leverage on operating expense. Our clinical excellence team had another busy quarter, with a full slate of new go-live implementations finished for new customers as well as for existing customers expanding into new locations. Four of the top 10 U.S. health systems were among them. We bring years of valuable experience to bear in supporting hospitals as they move from outsourced to in-source, beginning with a detailed project plan tailored to each hospital's needs, then carrying out that plan through nurse training, physician education and change management support. That all depends on smooth coordination across functions, and our teams keep coming through again and again. Past the rollout stage, members of our clinical excellence team work alongside customers to get the most out of Tablo across their whole system, helping pinpoint the outcomes each organization cares about most. Tablo's distinctive data ecosystem, which now holds over 10 trillion data points, lets us monitor and chart key performance indicators and share those insights with customers on a regular basis. This continuing partnership involves clinical and corporate leaders throughout our larger health systems, showing value, deepening customer ties and laying the groundwork for wider adoption system-wide. That dedication to producing measurable gains is turning into strong advocacy among customers. In a recent voice-of-the-customer evaluation run by a third-party consulting firm, Outset earned an overall customer satisfaction score above every health care benchmark that firm uses. The findings also revealed which aspects of Tablo customers prize most. Those surveyed gave Tablo high marks for timely dialysis that improves patient satisfaction, for reducing infrastructure burden and system costs, and for making dialysis delivery simpler through easier nurse training, mobility and ease of use. These results confirm Tablo's differentiated clinical, economic and operational value proposition and give our sales team what it needs to position Tablo as a platform for system-wide impact. We also used the chance to examine how well we keep customers over time. Since the commercial launch began, the figures indicated that cumulative retention among parent customers who purchased Tablo consoles is 96%. We attribute that result to our technology and equally to the full customer experience delivered by our team in areas including field service, clinical excellence, data analytics, EMR and many other functions within Outset. Robust customer advocacy combined with strong retention underpins all three drivers of future console growth: refresh sales, expansion sales and new customer sales. Our first meaningful refresh agreement, signed with HCA in Q2, strengthened one of the country's biggest health systems' long-term dedication to Tablo, contributed substantial contracted backlog and revenue visibility, and confirmed the refresh opportunity. Our sales team is actively working with other large health systems whose consoles are approaching end of life, and the progress encourages us. We think we are well positioned to extend this momentum across a refresh opportunity estimated at $150 million. Expansion sales represents another of our most compelling growth vectors. Our existing customer base is already familiar with our team, knows what implementation involves, and has firsthand knowledge of the advantages that in-source dialysis provides, and that makes the route from a single site's success to system-wide adoption noticeably smoother. We also have a strong base to build on. For instance, every one of the 14 biggest health systems, measured by estimated console opportunity, is already a customer of ours. Beyond that, Tablo is in service at one or more facilities belonging to roughly 50 of the 100 largest IDNs. This expansion revenue opportunity runs in both directions. To start, same-store sales growth refers to greater Tablo utilization within a given hospital site—for example, moving from Tablo use outside the ICU to the ICU as well, or the other way around. In either scenario, you need to buy more Tablo consoles and treat more volume. The second avenue for expansion is bringing Tablo into additional hospital facilities throughout the health system network. In Q3, we signed agreements along both of these expansion paths. Leveraging the extensive know-how of our new commercial leadership team, we are reshaping Outset's commercial model, which leaves us well positioned to deliver across all of these areas: refresh, expansion and new customer console sales. To give you one example, we're reducing the size of territories so reps can build deeper relationships, which is intended to accelerate how quickly pipeline converts. We've likewise adjusted compensation incentives to support our commercial priorities, and we're putting money into rewarding performance and shortening the time it takes to reach productivity. In parallel, we're expanding our capital sales team both regionally and at the national account level, so we can build deeper executive relationships and convert our impressive set of national contracts into system-wide adoption. Throughout sales, marketing, clinical, service and enterprise accounts, we operate as a single Outset, bringing our teams together behind a common objective, speeding adoption and driving conversion. We're doing this at a time when conditions for in-person dialysis are becoming more and more supportive. A couple of weeks back, HHS introduced the Kidney Care National Plan, which expands on federal dialysis priorities that were raised in 2019 via an executive order. Under this national plan, patients must have more choice, home dialysis has to be more widely accessible, and there need to be efforts promoting the adoption of new dialysis technologies. The plan also emphasizes reducing barriers for newcomers to dialysis services and aims to address practices that HHS considers anticompetitive and that it says keep physicians from offering patients a broader set of treatment options and new devices. These priorities are central to Outset's mission of driving fundamental change in dialysis delivery. HHS's commitment encourages us, as it aligns with what Tablo was designed to make possible—empowering health systems to bring dialysis in-house while giving patients more flexibility in where they choose to receive treatment. In time, shifts in market practices and new program initiatives could broaden patient access to home-based care and new home dialysis technologies like Tablo. Although the national plan's ultimate impact will depend on how it is implemented, we view it as a powerful acknowledgment of the need for change and a meaningful step toward a more competitive, innovative dialysis landscape. We think Outset is in a strong position to help lead that change, and we applaud HHS for moving better care for dialysis patients forward. On top of this new policy tailwind, the macro backdrop for Tablo looks attractive. Health systems are under mounting pressure to cut costs and raise care quality. Dozens of abstracts and papers by now confirm Tablo's clinical and financial benefits; in our view, the case for bringing dialysis in-house is exceptionally strong, given a simple, data-rich platform connected to the EMR that gives health systems more control over a critical service line. Tablo's chance to gain market share has never been more compelling. We know there is a lot of work still in front of us, yet Outset is well positioned to grow thanks to the right team and the right technology, and we look forward to the future; with that, I'll hand things over to Renee.
Renee Gaeta
executiveThank you, Leslie, and good afternoon to all of you. Revenue for the third quarter totaled $33.6 million, which represents growth of roughly 14% versus the same quarter a year ago. Product revenue came in at $23.7 million, a 15% increase over last year. Console revenue reached $10.5 million, rising 26% from a year earlier, while consumable revenue was $13.2 million, up 8% year-over-year. Service and other revenue totaled $9.9 million, an increase of 12% year-over-year. Recurring revenue — comprising consumables and service — amounted to $23.1 million, which is 10% higher than last year. Now let's move to the P&L. I'd ask you to consult the tables included in today's earnings release, which reconcile GAAP to non-GAAP measures. Non-GAAP gross margin for the third quarter came in at 40.8%, an increase of about 100 basis points versus last year, mainly reflecting product cost improvements, lower overhead and gains in service efficiency. Product gross margin was 44.2%, a decline of 150 basis points from last year, attributable to a greater mix of console sales within product revenue. Service and other gross margin reached 32.4%, 760 basis points higher than last year, as our attach rates for implementation and EMR software keep growing. Taken together, these results demonstrate sustained execution and keep us on the path toward our upcoming milestone of a 50% company-wide gross margin. Now on to operating expenses. We achieved more than 300 basis points of operating leverage. Non-GAAP operating expenses for the third quarter were $24.2 million. If you exclude roughly $1 million tied to bad debt expense, operating expenses rose just 4% while revenue grew 14%. Non-GAAP net loss was $12.9 million, versus a non-GAAP net loss of $12.4 million in the third quarter of last year. Let me turn to the balance sheet. We closed the quarter holding $140.7 million in cash, cash equivalents, short-term investments and restricted cash. Thanks to continued expense discipline and working capital management, cash use during the third quarter was $10.3 million, which keeps us on track to use approximately $40 million across the full year. Now for our guidance for 2026: we are reiterating our full year revenue guidance of $125 million to $130 million. We still expect full year non-GAAP gross margin to land in the low 40% to mid-40% range, and we'd remind you that a greater mix of console sales could push gross margin toward the lower end of that range. Our confidence in this outlook rests on a robust commercial pipeline and contracted backlog tied to the HCA refresh agreement; with that, I'll hand the call back to Leslie.
Leslie Trigg
executiveThanks, Renee. I’d like to wrap up by stressing the single word that summed up this quarter for Outset: execution. Our teams remained concentrated on the basics, and they successfully brought new sites online, broadened Tablo into more facilities at customers we already serve, fulfilled our first refresh agreement, and moved forward with preparations for the next generation of Tablo. We also increased our pipeline by engaging with customers both current and new. At the same time, we sped up revenue growth, achieved improvement in non-GAAP gross margin, and produced meaningful operating leverage. Going forward, our attention is on taking advantage of the three console growth drivers we have. The first one is the refresh chance, which represents over 3,000 consoles and roughly $150 million in potential revenue over the coming years. The second is the expansion chance, which includes both same-store sales of extra consoles and growth into new facilities; and the third is the big untapped white space of hospitals that haven't adopted Tablo yet. To help ensure we're well positioned to execute on all three of these growth drivers, we're widening our sales reach, boosting team capabilities, and adjusting sales compensation to accelerate our progress in our key commercial focus, the country's top 250 health systems. Our clinical excellence and customer success teams assist customers in realizing Tablo's complete value, establishing a basis for growing single-site relationships into partnerships across entire systems. Nothing here occurs by chance; it results from a team that arrives daily equipped with deep expertise and steadfast dedication to our customers and the patients they care for. I wish to thank our employees for the discipline and focus they contributed this quarter, and I also want to thank our customers and you, our shareholders, for your ongoing support. Our end market and the patients we serve require us. The reason our customers speak up on our behalf is the substantial, quantifiable value we've delivered so far over 4 million cumulative dialysis treatments; in a market whose dynamics keep getting more attractive, we stand out as the obvious technology leader. Outset has never faced a more compelling opportunity than the one in front of it. Our strategy, our technology, and our team are all in place, and we're eager to report on the progress we continue to make. That said, we're ready to take questions. Operator, please open the lines.
Josh Jennings
analystThis is Colin, in for Josh. I suppose it looks like there have been quite a few notable developments this year in the home setting. That HHS kidney care plan you brought up apparently puts some emphasis there. Vantiv appears to have divested its conventional hemodialysis business, yet is refocusing on home. And then we saw data at ASN indicating a chance to address a need involving peritoneal burnout in the home setting. I was wondering whether you could discuss how the home opportunity is shaping up for Outset this year, in 2026.
Leslie Trigg
executiveColin, this is Leslie. Thanks for asking. Yes, quite a few notable developments have actually come along here very recently. Let me address those individually, starting with HHS. We obviously need a clear picture of exactly how the policy will be carried out before we can gauge how the landscape might shift and, more to the point, how it could work in our favor by driving broader adoption of home care. That said, our overall read is that this is a very encouraging step. It brings back an earlier federal push on home dialysis—notably by recognizing certain gaps that need fixing, particularly around concentration and barriers to entry—and it could ease or expand the criteria for launching new home programs. Any of these has the potential to serve as a meaningful tailwind for us, though the full picture will only emerge over time. Yes, we view that as a potentially helpful policy shift that might spur adoption of new technologies and greater use of the home setting. Actually, at ASN this year and the year before, there was substantial discussion about home care, and I believe there was a lot of productive dialogue among physicians and growing momentum around the general question of how to encourage patients to be treated at home and to keep more of them there. And that, I think, is precisely where Tablo really distinguishes itself — both at the front end and over the long-term back end. As we expand our home business, the two KPIs we monitor are training metrics. We keep setting the pace, in my view, for how fast and simply patients along with their caregivers can be taught to use Tablo and head home. That, I believe, broadens the range of who is able to go home and how fast they can get there, in a genuinely favorable way. Then at the other end, retention rate is the KPI that matters most to us. Growing through long-term retention is precisely our strategy. And despite continuing to expand home and increase our patient census, we have held retention at the industry-leading level of 90% or higher during the first 90 days. Looking at the data, that 90-day retention figure turns out to be the strongest predictor and the best early signal of long-term retention at home. So we've continued to perform very well there, even as our home population increased. Lastly, I'd point out that we're growing both home and our patient base in two ways. First, we're deepening the patient census within the facilities and home programs that already offer Tablo and broad. We're seeing existing provider customers start to offer Tablo at more facilities and in more home programs. That's something we're excited about. And we continue to concentrate on our partnerships with the biggest MDOs—the midsized dialysis operators across the country. So there's plenty to discuss. I'm glad to field another question on home, Colin, if you have one. But I think each of these developments may signal that more will come to light, and they potentially do indicate certain upsides and certain tailwinds ahead when it comes to home.
Josh Jennings
analystGreat. My second question is probably a bit more focused on the acute side and the next-gen system rollout. I'm curious how things are going and what feedback you're hearing now that launch has been underway for a while. Sure. Okay, let me step back for a moment and discuss acute in broader terms; our commercial strategy for acute really has 3 parts.
Leslie Trigg
executiveOne, as I mentioned earlier in the prepared remarks, is the refresh opportunity. Two is expanding with existing customers, and that comes in 2 forms: same-store sales growth, adding new consoles, and broadening clinical use of Tablo within a given hospital setting; and three, naturally, is bringing on new customers. All 3 of those opportunities sit within our focus on the top 250 largest IDNs in the country; and why do we concentrate on the largest 250? Frankly, those institutions have the biggest potential console TAM as well as treatment volume TAM. That's where our commercialization organization has sharpened its focus and redoubled its efforts. On the next generation, to address your question, we keep moving forward through preparations for a full release. We are definitely still putting a high-quality customer experience ahead of speed. And luckily, we have the luxury of making sure we get it right; we feel very good about how it's developing, but we do want to ensure that the customer experience—especially since we now operate at a fairly substantial scale in terms of the console installed base and our customer installed base—is really done right from the start. So we'll keep progressing through that and look forward to seeing it in the market at scale over the coming months and quarters.
Kendall Au
analystNice work on the quarter. First thing I'd like to ask — I realize you've kept your top-line guidance where it was. Why not lift the bottom end, or adjust the outlook now that the quarter's behind us? And do you have anything to say about '27? What's a sensible starting point for revenue next year? Do you figure 10% growth year-over-year is within reach? I'd be glad to hear your thoughts on that as well.
Renee Gaeta
executiveKendall, Renee here. I appreciate the question. Those are quite good questions, and naturally they're front and center for us. With execution, 2026 matters a great deal to us. We stated this at the start of the year, and we have stayed firmly committed to it each quarter — our attention remains on keeping that discipline in how we guide and on executing against it as a top priority. Our pipeline keeps shifting, and remaining inside that disciplined guidance approach, we simply want to ensure we position ourselves well, and we concluded that as we stand here today reporting Q3, we are where we expected to be. We are truly pleased with how this year has gone. Looking at every model currently available, you'll notice that the second half of 2026 already incorporates fairly substantial growth rates. For the time being, we're at ease keeping that as is, and we're eager to discuss 2027 in greater depth when we report Q4. One thing I can state is that naturally, our goal is to get back to being a company growing at a double-digit pace, and this organization is absolutely concentrated on its capacity to deliver on that.
Kendall Au
analystYeah, I appreciate that, and I've got one quick question to add on top of it. Are you seeing any significant shifts in the CapEx environment as we head into '27? Do you have expectations of, like, perhaps a slowdown? Or do you think the spending pattern will stay consistent next year? I'd just love to hear any comments on that.
Leslie Trigg
executiveYes. Kendall, it's Leslie here. We haven't so far. Obviously, that's subject to change, and all of us on the capital equipment side are, obviously, in active monitoring mode; but from what we've been through and what we're hearing and talking over with customers, we aren't seeing or perceiving any major shifts in the capital spending climate right now.
Leslie Trigg
executiveThank you all for being here today. Before we finish, I want to express appreciation to our customers and to our team for the difference they make each day in the lives of dialysis patients. Have a wonderful afternoon and evening.
Operator
operatorThanks. That brings us to the end of today’s conference call. We appreciate your participation, and you’re welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Outset Medical, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Outset Medical, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Outset Medical, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.